Structure Therapeutics Inc
NASDAQ:GPCR

  • LAST PRICE
    33.1500
  • TODAY'S CHANGE (%)
    -0.6000 (-1.7778%)
  • Bid / Lots
    33.1600/ 1
  • Ask / Lots
    33.6400/ 3
  • Open / Previous Close
    33.7800 / 33.7500
  • Day Range
    32.8300
    34.6445
  • 52 Week Range
    26.6100
    66.3800
  • Volume
    240,485

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
GPCR
Structure Therapeutics Inc
1.9B
-15.0x
---
IRON
Disc Medicine Inc
1.9B
-16.0x
---
NAMS
NewAmsterdam Pharma Company NV
1.9B
-8.9x
---
CLDX
Celldex Therapeutics Inc
1.9B
-10.7x
---
BLTE
Belite Bio Inc
2.1B
-57.1x
---
TARS
Tarsus Pharmaceuticals Inc
1.9B
-14.0x
---
As of 2024-12-01

Company Information

Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases. It is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE-2578. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is developing GLP-1R candidates, including dual GLP-1R/GIPR agonists and amylin agonists, each designed with customized properties to achieve additional benefit. It is developing ANPA-0073, an investigational oral small molecule APJR agonist, for the treatment of idiopathic pulmonary fibrosis (IPF). It is evaluating its LPA1R program, LTSE-2578 for IPF and progressive pulmonary fibrosis.

Contact Information

Headquarters
611 Gateway Blvd Suite 223SOUTH SAN FRANCISCO, CA, United States 94080
Phone
---
Fax
---

Executives

Independent Chairman of the Board
Daniel Welch
Director
Raymond Stevens
Chief Financial Officer
Jun Yoon
Chief Technology Officer
Yingli Ma
Chief Scientific Officer
Xichen Lin

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$1.9B
Revenue (TTM)
$0.00
Shares Outstanding
57.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.21
Book Value
$9.76
P/E Ratio
-15.0x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.